Panelists discuss how real-world practice often diverges from guideline recommendations due to access barriers, toxicity ...

Quality of life emerges as a central theme, with panelists emphasizing that patient-reported outcomes and psychosocial ...

Panelists discuss how the next generation of targeted agents, including sunvozertinib, BLU-945, and antibody-drug conjugates, ...

The TKI plus InO-based therapy for newly diagnosed Ph+ ALL successfully met the efficacy end point, achieving an 81% MR3+ rate within 2 courses with limited cycles of InO. The modified schema 2 ...

The ACCESS trial shows mismatched unrelated donors can provide excellent outcomes, addressing racial disparities in donor ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

The combination of talquetamab-tgvs and pomalidomide achieved an 85.7% objective response rate in relapsed/refractory multiple myeloma patients. Median progression-free survival was 25.8 months, with ...

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...

The LimiTEC trial explored teclistamab discontinuation in multiple myeloma, showing comparable outcomes to continuous therapy with a median PFS of 19.9 months. Fixed-duration therapy may reduce ...

XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...

James Essell, MD, Sarah Cannon Research Institute at OHC, the US Oncology Network, discusses the benefits of a remote ...